Related Experiment Video
Updated: Jun 12, 2026

Isolation and Expansion of Mesenchymal Stem/Stromal Cells Derived from Human Placenta Tissue
Published on: June 6, 2016
Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging
Svetlana Halfon1, Natalie Abramov, Borislava Grinblat
1Teva Pharmaceutical Industries, Rehovot, Israel .
Abstract:
Expansion of plastic-adherent bone marrow-derived mesenchymal stem cells (MSCs) results in gradual loss of osteogenic potential after passage 5-6. One explanation is contamination of MSC cultures with mature cells including fibroblasts. Identification and elimination of fibroblasts from MSC cultures could improve MSC yield and differentiation potential and also prevent tumor formation after MSC transplantation. However, no specific markers currently exist that can reliably discriminate between MSCs and fibroblasts. Flow cytometry analysis demonstrated that markers currently used to define MSCs, such as CD105, CD166, CD90, CD44, CD29, CD73, and CD9, are also expressed on human skin or lung fibroblasts. However, the level of expression of CD166 was significantly higher and that of CD9 was significantly lower in MSCs than in fibroblasts. CD146 was expressed only in MSCs. Using small focused microarrays, new markers differentially expressed in MSCs and fibroblasts were identified. Real-time polymerase chain reaction confirmed that expression of CD106, integrin alpha 11, and insulin-like growth factor-2 in MSCs was at least 10-fold higher than in fibroblasts; whereas expression of matrix metalloproteinase 1 and matrix metalloproteinase 3 was almost 100-fold lower. Flow cytometry and immunostaining demonstrated that CD106 protein expression on cell surface could be upregulated in MSCs but not in fibroblasts by the treatment with tumor necrosis factor-alpha. Comparison of surface expression of commonly used and newly identified MSC markers in MSCs cultures of passage 2 and passage 6 demonstrated that CD106 (with and without tumor necrosis factor-alpha treatment), integrin alpha 11, and CD146 were downregulated in MSCs of passage 6, and CD9 was upregulated; whereas all other markers did not change. Newly identified markers that have robust differences of expression in MSCs and fibroblasts on gene and protein level could be used for quality control of MSC cultures after expansion, cryopreservation, gene transfection, and other manipulations.
Insights
Identifying reliable markers to distinguish mesenchymal stem cells (MSCs) from fibroblasts is crucial for cell therapy. New markers like CD106 and integrin alpha 11 show promise for MSC quality control.
Area of Science:
- Cell Biology
- Stem Cell Research
- Biotechnology
Background:
- Mesenchymal stem cells (MSCs) lose osteogenic potential with expansion, potentially due to fibroblast contamination.
- Current MSC markers are also found on fibroblasts, hindering accurate identification.
- Distinguishing MSCs from fibroblasts is vital for therapeutic applications and preventing tumor formation.
Purpose of the Study:
- To identify novel markers that can reliably differentiate between bone marrow-derived MSCs and fibroblasts.
- To evaluate the expression of these markers in MSCs at different passages and after specific treatments.
- To establish methods for quality control of MSC cultures.
Main Methods:
- Flow cytometry and small focused microarrays were used to analyze marker expression.
- Real-time polymerase chain reaction (PCR) quantified gene expression differences.
- Immunostaining and cell surface protein expression analysis were performed.
- MSCs were treated with tumor necrosis factor-alpha (TNF-α) to assess CD106 regulation.
Main Results:
- CD146 was exclusively expressed on MSCs.
- CD106, integrin alpha 11, and insulin-like growth factor-2 showed significantly higher expression in MSCs compared to fibroblasts.
- CD106, integrin alpha 11, and CD146 downregulated in later passage MSCs, while CD9 upregulated.
- CD106 expression could be upregulated in MSCs by TNF-α treatment.
Conclusions:
- Novel markers, including CD106, integrin alpha 11, and CD146, can effectively distinguish MSCs from fibroblasts.
- These markers are valuable for assessing MSC quality during expansion, cryopreservation, and other manipulations.
- The identified markers offer improved quality control for MSC-based therapies.

